Antiemetic Drugs Market - Forecast(2024 - 2030)

Antiemetic Drugs Market Overview

Antiemetic Drugs Market size is estimated to reach $6.1 billion by 2027, growing at a CAGR of 5.3% during the forecast period 2022-2027. Antiemetic drugs fall under the category of therapeutic drugs which are taken into account to treat uncontrollable reflexes like nausea and vomiting. This uneasiness or sudden urge to eject the content of the stomach is often triggered by vestibular illnesses, digestion problems, pregnancy, and acts as an emetogenic chemotherapeutic agent. Dopamine receptors, histaminergic receptors, and various antagonists are used as first-line treatments to cure the urge to vomit. With advancements in mediums of transportation and connectivity many people nowadays are prone to motion sickness. While traveling it becomes hard for the brain to figure out whether the body is moving or motionless because various motion-sensing parts confuse it by sending contradictory signals. The outlook for the antiemetic drugs market is remarkably captivating with growing cancer complications worldwide. Heightened mobility of people with escalating per capita income, proliferation in cancer complications are factors set to drive the growth of the Antiemetic Drugs Market for the period 2022-2027.

Report Coverage

The report: “Antiemetic Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antiemetic Drugs Market.

By Type: Cannabinoids, Serotonin and Dopamine antagonists, NK1 receptor antagonist, Benzodiazepines, 5-HT3 receptor, Anticholinergic, Steroid-corticosteroids, and others.
By Application: Migraine, Anesthesia, Vestibular illnesses, Pregnancy, Chemotherapy, Opioid analgesics, Palliative care, Gastroenteritis, Opioid-induced nausea.
By Distribution Channel: Offline and Online platforms.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

• Geographically, the North America Antiemetic Drugs Market accounted for the highest revenue share in 2021. It is owing to the vast array of population receiving chemotherapy treatments which in turn enforces people to start on medications related to antiemetics. However, Asia-pacific is expected to offer lucrative growth opportunities to the marketers in the projected period of 2022-2027 owing to a substantial shift of government’s focus to enhance the medicinal reach and pro-active budget allocation.
• Enlarging research activities for novel drug discovery is said to be a preeminent driver driving the growth of the Antiemetic Drugs Market. Side-effects connected with the overuse of antiemetic drugs are said to reduce the market growth.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Antiemetic Drugs Market report.

Antiemetic Drugs Market Segment Analysis-By Application

The Antiemetic Drugs Market based on the application type can be further segmented into migraine, anesthesia, vestibular illnesses (=motion sickness), pregnancy, chemotherapy, opioid analgesics, palliative care, gastroenteritis, opioid-induced nausea. The chemotherapy and pregnancy-induced nausea and vomiting held the largest segment in 2021. The growth in cancer treatment procedures like chemotherapy is owing to the heightened number of cancer patients worldwide. Bad ingestion habits, excess use of alcohol and smoking, worsening pollution situations are some common reasons behind soaring cancer cases. Furthermore, nausea and vomiting are very common during pregnancies which have made usage of antiemetic drugs a norm. The vestibular illnesses and chemo-induced vomiting segment is estimated to be the fastest-growing segment with a CAGR of 5.9% over the forecast period 2022-2027. This growth is owing to the mounting usage of antiemetic drugs during traveling and chemotherapies. Cardiovascular diseases are the leading cause of death around the globe. Around 30-32% of demises worldwide occur due to cancer and heart attacks. Considering the vulnerable immunity, the number is anticipated to rise in foreseeable future.

Antiemetic Drugs Market Segment Analysis-By Distribution Channel

The Antiemetic Drugs Market based on distribution channels can be further segmented into hospital pharmacies, retail pharmacies, drug stores, and others. The hospital segment held the largest share in 2021. The growth is owing to the upsurging number of pregnancy treatments and cancer-associated treatments like chemotherapy. With rapid modernization, a huge shift in attitudes of people from treatments to prevention can be witnessed. Therefore, broadening health awareness among people encourages them to undergo all necessary procedures well in advance. Moreover, the refining infrastructure of hospitals and other medical facilities is contributing factor in the growth of the antiemetic drugs market. There are around 71 NCI designated Cancer hospitals within the 36 states and District of Columbia, which further eases the use of drugs pertaining to nausea. However, the retail pharmacies segment is estimated to be the fastest-growing segment with a CAGR of 6.2% over the forecast period 2022-2027. This growth is owing to the across-the-board presence of retail pharmacies in urban as well as rural areas. On another hand, augmenting the application of antiemetic drugs in the treatment of motion sickness encourages people to buy such medication over-the-counter without any prior prescription from doctors.

Antiemetic Drugs Market Segment Analysis-By Geography

The Antiemetic Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 34% of the overall market in 2021. The growth in this segment is owing to the factors such as the higher prevalence of breast and lung cancer cases among the American population. Attributing to full-fledged economies North-American people enjoy a high standard of living. Additionally, they have access to the world’s best healthcare facilities such as hospitals and diagnostic laboratories which is a prominent factor fueling the growth in the respective segment. Nevertheless, the Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to shooting up cancer prevalence due to the broadening geriatric population, enlarging affluence of Asian nations. As per capita income of Asian states is augmenting people are buying their personal vehicles which are resulting in expansion of traveling trips. The poor quality and unhygienic buses and trains in the nations like India is another factor that stimulated the urge because for impoverished and middle-class sections the public transportation is the most common way of commuting from one place to other. India saw a 137% increase in its healthcare budget allocation which would prove out to help those who need it the most, especially the underprivileged cancer patients requiring chemotherapy.

Antiemetic Drugs Market Drivers

The proliferating pervasiveness of cancer is Anticipated to Boost Product Demand

Following heart-attack cancer is the second biggest cause stimulating the death figures throughout the globe. Every year around 9-10 million people lose their life to it. Breast and lung cancer are the two main categories as their prevalence has augmented on an unprecedented scale. With 2.3 million diagnosed cases in 2020, breast cancer claimed the lives of more than 680,000 people worldwide. Similarly, with the escalating smoking trend, the pervasiveness of lung cancer is growing. According to a study, 82% of lung cancer complications are caused by smoking. On another hand, accruing the old-age population is another prominent factor in the growth of the antiemetic drugs market.

Accruing per capita income is Expected to Boost Product Demand

Rapid modernization and industrialization around the globe are fueling the per capita income of countries. If we compare the last two decades The unemployment rates have reduced as people today have more means to earn a living as compared to earlier times. The trends of buying personal vehicles, exploring the world, and visiting amusement parks have multiplied in recent years which is a prominent factor in the growth of the respective market. More than 17% of the world population has their own cars and the number is expected to accrue in upcoming years as purchasing power is expanding. Many European country’s per capita has crossed the $65000 mark. Besides, the living standard in the so-called third world is improving. People are traveling more than ever with the availability of adequate transportation. All these aforementioned factors are prompting the use of antiemetic drugs.

Antiemetic Drugs Market Challenges

Health hitches associated with overuse of antiemetic drugs are Anticipated to Hamper Market Growth

There are several adverse side effects accompanied by the use of antiemetic drugs which are anticipated to cripple the growth of the antiemetic market. These effects can be life-threatening in a few cases. Anticholinergic effects which include tachycardia, constipation, hallucinations, schizophrenia are connected with the use of dopamine antagonists. Furthermore, antiemetic drugs including serotonin antagonists, benzodiazepines, and cannabinoids may lead to several other health hitches like QT prolongation, extrapyramidal symptoms (=akathisia, dystonia, and parkinsonism), sedition.

Antiemetic Drugs Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antiemetic Drugs Market. The Top-10 Key companies of Antiemetic Drugs Market are-

1. Abbott
2. Sanofi-Aventis
3. GlaxoSmithKline
4. F. Hoffmann-La Roche
5. Merck & Co.
6. Novartis AG
7. Baxter International
8. Eisai Co.
9. Daiichi Sankyo
10. Eli Lily and Company

Recent Developments/Product Launches:

• On November 9, 2021, “Sanofi”, a healthcare company based in Paris, France announced the acquisition of “Kadmon Corporation.” Kadmon is a US-based biopharma company that develops various therapies. Sanofi wrapped up the acquisition process with a payment of $1.9 billion. The existing shareholders are going to get $9.50 per share. Additionally, Sanofi’s price tag has been representing a 79% premium over the Kadmom close price of $5.30. Further, Sanofi has been under pressure owing to its slow drug pipeline presence.
• On July 14, 2021, Indiana, United States-based pharmaceutical company “Eli Lilly and Company” announced the successful acquisition of biotechnology firm “Protomer technologies.” Protomer is famous for its advanced protein therapy production. The company's proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with a tunable activity that can be controlled using small molecules. Moreover, the transaction is brought to an end with a payment of $1 billion.
• On March 15, 2021, a Switzerland-based multinational health firm “F. Hoffman-la Roche” announced that it has reached an agreement with GenMark Diagnostics, a company that provides diagnostic solutions and is headquartered in California, United States. Roche paid $1.8 billion in order to bring the deal to an end. Moreover, every existing shareholder of GenMark will receive $24.05 per share.

Relevant Links:

Asia and ASEAN Herbal Medicines Market – Forecast (2022 - 2027)

Report Code: HCR 1347

Branded Generics Market – Forecast (2022 - 2027)

Report Code: HCR 0255

For more Lifesciences and Healthcare Market reports, please click here